2.1 Table of Contents of Module 2
-----------------------------------

Section	Contents	
2.1	CTD Table of Contents	
2.2	Introduction	
2.3	Quality Overall Summary (QOS)	
2.3.S	DRUG SUBSTANCE- Cabazitaxel (CEP#: R0-CEP 2009-270-Rev	
	01)	
2.3.S.1	General Information	
2.3.8.2	Manufacture	
2.3.8.3	Characterisation	
2.3.S.4	Control of Drug Substance	
2.3.8.5	Reference Standards or Materials	
2.3.8.6	Container-Closure System	
2.3.8.7	Stability	
2.3.P	DRUG PRODUCT	
2.3.P.1	Description and composition of the drug product	
2.3.P.2	Pharmaceutical development	
2.3.P.3	Manufacture	
2.3.P.4	Control of Excipients	
2.3.P.5	Control of Drug Product	
2.3.P.6	Reference standards or materials	
2.3.P.7	Container closure system	
2.3.P.8	Stability	

Section	Contents
2.3.A	Quality Overall Summary – Appendices
2.3.R	Quality Overall Summary – Regional information
2.4	Non-clinical Overview
2.5	Clinical Overview
2.6	Non-clinical Written and Tabulated Summaries
2.7	Clinical Summary

Section	Contents			
List of abbreviations used in dossier				
3.1	Module 3 Table of Contents			
3.2	Body of Data			
3.2.S	DRUG SUBSTANCE			
3.2.S.1	General Information			
3.2.S.1.1	Nomenclature			
3.2.S.1.2	Structure			
3.2.S.1.3	General Properties			
3.2.S.2	Manufacture			
3.2.S.2.1	Manufacturer(s)			
3.2.S.2.2	Description of manufacturing process and process controls			
3.2.S.2.3	Control of materials			
3.2.S.2.4	Controls of critical steps and intermediates	The information		
3.2.S.2.5	Process validation and / or evaluation	contained in this section is disclosed in Restricted Part.		
3.2.S.2.6	Manufacturing process development			
3.2.8.3	Characterization			
3.2.S.3.1	Elucidation of structure and other characteristics	2S		
3.2.S.3.2	Impurities			
3.2.8.4	Control of Drug Substance			
3.2.S.4.1	Specification			
3.2.S.4.2	Analytical procedures			
3.2.S.4.3	Validation of analytical procedures			
3.2.S.4.4	Batch Analysis			

Section	Contents	
3.2.S.4.5	Justification of Specification	
3.2.8.5	Reference Standards or materials	
3.2.8.6	Container closure system	
3.2.S.7	Stability	
3.2.S.7.1	Stability summary and conclusions	
3.2.S.7.2	Post – approval stability protocol and stability commitment	
3.2.S.7.3	Stability data	
3.2.P	DRUG PRODUCT	
3.2.P.1	Description and Composition of the Drug Product	
3.2.P.2	Pharmaceutical Development	
3.2.P.3	Manufacture	
3.2.P.3.1	Manufacturer	
3.2.P.3.2	Batch Formula	
3.2.P.3.3	Description of Manufacturing Process and Process	
3.2.P.3.4	Controls of Critical Steps and Intermediates	
3.2.P.3.5	Process Validation and/or Evaluation	
3.2.P.4	Control of Excipients	
3.2.P.4.1	Specification	
3.2.P.4.2	Analytical Procedures	
3.2.P.4.3	Validation of Analytical Procedure	
3.2.P.4.4	Justification of Specifications	
3.2.P.4.5	Excipients of Human or Animal Origins	
3.2.P.4.6	Novel Excipients	

Section	Contents
3.2.P.5	Control of Drug Product
3.2.P.5.1	Specification(s)
3.2.P.5.2	Analytical Procedures
3.2.P.5.3	Validation of Analytical Procedures
3.2.P.5.4	Batch Analysis
3.2.P.5.5	Characterisation of Impurities
3.2.P.5.6	Justification of Specification(s)
3.2.P.6	Reference Standards or Materials
3.2.P.7	Container Closure System
3.2.P.8	Stability
3.2.P.8.1	Stability Summary and Conclusion
3.2.P.8.2	Post-approval Stability Protocol and Stability Commitment
3.2.P.8.3	Stability Data
3.2.A	Appendices
3.2.A.1	Facilities and Equipment
3.2.A.2	Adventitious Agents Safety Evaluation
3.2.A.3	Excipients
3.2.R	Regional information